TICKERNERD
Menu
PMVPPMVPHealthcare · Biotechnology

PMVP Stock Forecast: PMV Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.42
−1.39% on the day

The 6 Wall Street analysts covering PMV Pharmaceuticals, Inc. hold a median 12-month price target of $4 — +181.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$75.9M
Ticker Nerd rank
78 / 100
Median analyst target
$4.00
Analysts covering
6
Revenue$0.0
Operating income−$18.9M
Net income−$18.1M
Free cash flow−$14.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+14.5%
1M
+9.2%
YTD
+13.6%
1Y
+15.4%
From 52W high
−21.1%
From 52W low
+39.2%
$1.02
$1.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PMVP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PMV Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
85
Growth
80
Size
75
Accruals
71
Issuance
68
Revisions
62
Momentum
58
Quality
39
Value
37

Volatility (85): The share price has been relatively steady.

Value (37): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PMVP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PMVP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26PMVPHigh $5.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $3.00Median $4.00High $5.00

The green dot is the last close — the median target sits +181.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Sept 2026HC Wainwright & Co.ReiteratesBuy$5.00
8 July 2026Ladenburg ThalmannAssumesBuy$3.00
13 May 2026OppenheimerMaintainsOutperform—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
20 Aug 2024HC Wainwright & Co.ReiteratesBuy—
30 May 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024Craig-HallumInitiatesBuy—
12 Apr 2024JefferiesInitiatesBuy—
7 Mar 2024HC Wainwright & Co.ReiteratesBuy—
27 Dec 2023Ladenburg ThalmannInitiatesBuy—
16 Oct 2023HC Wainwright & Co.MaintainsBuy—
11 Aug 2023HC Wainwright & Co.MaintainsBuy—
17 May 2023HC Wainwright & Co.ReiteratesBuy—
11 May 2023OppenheimerReiteratesOutperform—
20 Mar 2023HC Wainwright & Co.MaintainsBuy—
2 Mar 2023OppenheimerMaintainsOutperform—
17 Nov 2022HC Wainwright & Co.MaintainsBuy—
9 June 2022OppenheimerMaintainsOutperform—
24 May 2022Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PMVP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PMVP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, PMV Pharmaceuticals, Inc. returned +15.4% against +17.5% for the S&P 500, dividends included.

PMVP vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Oct 25Jan 26Apr 26Jul 26PMVPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PMVP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

PMV Pharmaceuticals, Inc. (PMVP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
1.0×

Cheaper than 72% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−70.9%

Higher than 17% of US stocks

Return on assets
−42.4%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PMV Pharmaceuticals, Inc. (PMVP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PMV Pharmaceuticals, Inc. has a market value of $75.9M and an enterprise value of −$4.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$75.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$71.3M.

  • Shares outstanding: 53.5M.

  • Trailing P/E: −1.0×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • PMV Pharmaceuticals, Inc. employs 54 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

PMVP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PMVPPMV Pharmaceuticals, Inc.$75.9M
78
PYPDPolyPid Ltd.$104.6M
52
COYACoya Therapeutics, Inc.$102.7M
58
SEERSeer, Inc. (California)$109.7M
72
GUTSFractyl Health, Inc.$101.5M
31
GNLXGenelux Corp.$111.3M
22
PLYXPolaryx Therapeutics, Inc.$100.2M
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PMV Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PMVP news & analysis

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

GlobeNewsWire · 1 Sept 2026neutral

PMV Pharmaceuticals announced the pricing of an oversubscribed underwritten public offering of $50 million, comprising 22,055,000 shares of common stock, pre-funded warrants for up to 19,900,000 shares, and accompanying warrants to purchase 41,955,000 shares at an initial exercise price of $1.21 per share.

Why it matters — PMVP watchers would care because the capital raise provides the company with additional funding for its p53-targeting precision oncology programs.

PMV Pharma Announces Proposed Public Offering of Securities

GlobeNewsWire · 31 Aug 2026neutral

PMV Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock, accompanying warrants, and, for certain investors, pre-funded warrants and accompanying warrants, with all securities to be sold by the company. The offering is subject to market and other conditions, and there is no assurance it will be completed or as to its size or terms.

Why it matters — PMVP watchers would care because this proposed offering could affect the company's capital position and share structure.

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

GlobeNewsWire · 31 Aug 2026positive

PMV Pharmaceuticals announced updated interim ovarian cancer data from the Phase 2 pivotal portion of its PYNNACLE clinical trial, assessing rezatapopt as a monotherapy (2000 mg once daily) in patients with TP53 Y220C advanced solid tumors.

Why it matters — The updated interim data from the registrational Phase 2 trial informs the clinical progress of rezatapopt, PMV Pharma's lead investigational therapy in a pivotal ovarian cancer study.

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 19 Aug 2026positive

PMV Pharmaceuticals (PMVP) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade signals increased confidence in PMVP's near-term outlook.

Why it matters — A PMVP watcher would care because the upgrade reflects improved earnings expectations that could influence how the market views the stock.

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

GlobeNewsWire · 14 Aug 2026neutral

PMV Pharmaceuticals reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is a precision oncology firm focused on developing small molecule therapies targeting p53.

Why it matters — PMVP watchers would care because the quarterly financial results and corporate update provide a routine but important update on the company's progress and financial standing.

FAQ

Frequently asked questions about PMVP stock

What is the PMVP stock price forecast for 2026-2027?

The 6 Wall Street analysts covering PMV Pharmaceuticals, Inc. have a median 12-month price target of $4, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PMVP stock a buy right now?

Of the 6 analysts covering PMV Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PMV Pharmaceuticals, Inc. 78 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PMVP?

As at 12 Sept 2026, PMV Pharmaceuticals, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (85 of 100).

Will PMVP stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +181.7% from the last close, and Ticker Nerd's factor model ranks PMV Pharmaceuticals, Inc. 78 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PMVP stock forecast for 2030?

No analyst covering PMV Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMVP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.

How has PMVP stock performed over the past year?

PMV Pharmaceuticals, Inc. returned +15.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PMV Pharmaceuticals, Inc. do?

PMV Pharmaceuticals, Inc. is a precision oncology biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations in cancer.

What is the latest news on PMVP?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities". PMV Pharmaceuticals announced the pricing of an oversubscribed underwritten public offering of $50 million, comprising 22,055,000 shares of common stock, pre-funded warrants for up to 19,900,000 shares, and accompanying warrants to purchase 41,955,000 shares at an initial exercise price of $1.21 per share.

Company

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. is a precision oncology biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations in cancer. The company’s lead program, rezatapopt, is designed as a selective p53 reactivator for tumors carrying the Y220C mutation, with a tumor-agnostic approach that aims to address cancers across multiple tissue types. PMV Pharmaceuticals concentrates on translational research and clinical development for advanced solid tumors, combining drug discovery with mutation-specific biology to create targeted treatment options. Based in Princeton, New Jersey, the company operates within the broader cancer therapeutics market and is recognized for its work in mutant p53 biology and small-molecule precision medicine.

CEO Dr. David H. Mack Ph.D. · 54 employees · United States · https://www.pmvpharma.com